Here are seven highlights:
1. The company anticipated preliminary and unaudited revenue to hit between $32.5 million and $32.7 million for Q4 2016. This range reflects about a 6 percent decrease compared to Q4 2015.
2. SeaSpine expects spinal hardware revenue to account for about $15.9 million and orthobiologics revenue to hit $16.7 million.
3. Total U.S. revenue likely decreased about 4 percent to $29.9 million in Q4 2016, compared to Q4 2015.
4. For FY 2016, SeaSpine expects preliminary and unaudited revenue to reach between $128.8 million and $129 million.
5. The company’s cash and cash equivalents at Dec. 31, 2016, will likely reach $14.6 million.
6. Outstanding borrowings under the credit facility will be about $3.8 million.
7. SeaSpine will release full-year 2017 revenue guidance in March 2017.
More articles on devices:
Where NuVasive will focus in the future — Alignment, radiation reduction and more
Johnson & Johnson Medical Device Companies launches orthopedic episode of care platform: 5 things to know
Mainstay Medical CEO to present at Medtech Showcase: 3 points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
